[
    {
        "other_ids": [
            {
                "name": "Study Protocol Other Identifier",
                "value": "NRG-BR1428"
            }
        ],
        "amendment_date": "2019-07-29",
        "keywords": null,
        "dcp_id": null,
        "interventional_model": "Parallel",
        "lead_org": "NRG Oncology",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "All of the following staging criteria (according to the 7th edition of the American Joint Committee on Cancer [AJCC] Cancer Staging Manual) must be met:\r\n* By pathologic evaluation, primary tumor must be pT1-3\r\n* By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN2b, pN3a, or pN3b\r\n* If pN0, pathological tumor must be >= 3.0 cm"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 5,
                    "description": "The tumor must have been determined to be human epidermal growth factor receptor 2 (HER2)-negative as follows:\r\n* Immunohistochemistry (IHC) 0-1+; or\r\n* IHC 2+ and in situ hybridization (ISH) non-amplified with a ratio of HER2 to centromere enumerator probe 17 (CEP17) < 2.0, and if reported, average HER2 gene copy number < 4 signals/cells; or\r\n* ISH non-amplified with a ratio of HER2 to CEP17 < 2.0, and if reported, average HER2 gene copy number < 4 signals/cells"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 6,
                    "description": "The tumor must have estrogen receptor (ER)-and progesterone receptor (PgR)-status assessed using current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines; patients are eligible if the tumor staining meets one of the following criteria:\r\n* ER-negative and PgR- negative by ASCO/CAP guidelines, OR\r\n* ER or PgR stains are positive in 1-9% of cells and neither is positive in >= 10% of cells"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 7,
                    "description": "The patient must have undergone either a mastectomy (total, skin-sparing, or nipple-sparing) or lumpectomy"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 8,
                    "description": "For patients who undergo lumpectomy, the margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the local pathologist; if pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obtain clear margins; if tumor is still present at the resected margin after re-excision(s), the patient must undergo mastectomy to be eligible; (patients with margins positive for lobular carcinoma in situ [LCIS] are eligible without additional resection)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 9,
                    "description": "For patients who undergo mastectomy, the margins must be free of residual gross tumor; (patients with microscopic positive margins are eligible as long as post-mastectomy radiation therapy [RT] of the chest wall will be administered)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 10,
                    "description": "The patient must have completed one of the procedures for evaluation of pathologic nodal status listed below.\r\n* Sentinel lymphadenectomy alone:\r\n** If pathologic nodal staging based on sentinel lymphadenectomy is pN0 or pN1b;\r\n** If pathologic nodal staging based on sentinel lymphadenectomy is pN1mi or pN1a and the patient has undergone breast conserving surgery (with planned breast radiotherapy), the primary tumor must be T1 or T2 by pathologic evaluation and the nodal involvement must be limited to 1 or 2 positive nodes\r\n* Sentinel lymphadenectomy followed by removal of additional non-sentinel lymph nodes if the sentinel node (SN) is positive; or\r\n* Axillary lymphadenectomy with or without SN isolation procedure"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 11,
                    "description": "The interval between the last surgery for breast cancer (including re-excision of margins) and randomization must be no more than 60 days"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 12,
                    "description": "Absolute neutrophil count (ANC) must be >= 1200/mm^3 (within 6 weeks prior to randomization)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 13,
                    "description": "Platelet count must be >= 100,000/mm^3 (within 6 weeks prior to randomization)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 14,
                    "description": "Hemoglobin must be >= 10 g/dL (within 6 weeks prior to randomization)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 15,
                    "description": "Total bilirubin must be =< upper limit of normal (ULN) for the laboratory (lab) unless the patient has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert\u2019s disease or similar syndrome involving slow conjugation of bilirubin (within 6 weeks prior to randomization)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 16,
                    "description": "Alkaline phosphatase must be =< 2.5 x ULN for the lab (within 6 weeks prior to randomization)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 17,
                    "description": "Aspartate aminotransferase (AST) must be =< 1.5 x ULN for the lab (within 6 weeks prior to randomization)\r\n* Note: If alanine aminotransferase (ALT) is performed instead of AST (per institution's standard practice), the ALT value must be =< 1.5 x ULN; if both were performed, the AST must be =< 1.5 x ULN"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 18,
                    "description": "Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]-CT, or PET scan) performed within 90 days prior to randomization does not demonstrate metastatic disease and the requirements above are met"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 19,
                    "description": "Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 90 days prior to randomization does not demonstrate metastatic disease"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 20,
                    "description": "Adequate renal function determined within 6 weeks prior to randomization defined as the most recent serum creatinine =< ULN or measured or calculated creatinine clearance > 60 mL/min"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 21,
                    "description": "Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days prior to randomization; (LVEF assessment performed by 2-dimensional [D] echocardiogram is preferred; however, multi gated acquisition [MUGA] scan may be substituted based on institutional preferences;) the LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normal"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 22,
                    "description": "T4 tumors including inflammatory breast cancer"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 23,
                    "description": "Definitive clinical or radiologic evidence of metastatic disease; required imaging studies must have been performed within 90 days prior to randomization"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 24,
                    "description": "Synchronous or previous contralateral invasive breast cancer; (patients with synchronous and/or previous contralateral DCIS or LCIS are eligible)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 25,
                    "description": "Any previous history of ipsilateral invasive breast cancer or ipsilateral DCIS; (patients with synchronous or previous ipsilateral LCIS are eligible)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 26,
                    "description": "History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 27,
                    "description": "Previous therapy with anthracyclines or taxanes for any malignancy"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 28,
                    "description": "Chemotherapy administered for the currently diagnosed breast cancer prior to randomization"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 29,
                    "description": "Any continued use of sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy; patients are eligible if these medications are discontinued prior to randomization"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 30,
                    "description": "Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens; this includes but is not confined to:\r\n* Active cardiac disease\r\n** Angina pectoris that requires the current use of anti-anginal medication;\r\n** Ventricular arrhythmias except for benign premature ventricular contractions;\r\n** Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication;\r\n** Conduction abnormality requiring a pacemaker;\r\n** Valvular disease with documented compromise in cardiac function; or\r\n** Symptomatic pericarditis\r\n* History of cardiac disease\r\n** Myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricle (LV) function;\r\n** History of documented congestive heart failure (CHF); or\r\n** Documented cardiomyopathy"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 31,
                    "description": "Uncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg; (patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 32,
                    "description": "Active hepatitis B or hepatitis C with abnormal liver function tests"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 33,
                    "description": "Patients known to be human immunodeficiency virus (HIV) positive with a baseline cluster of differentiation (CD)4 count of < 250 cells/mm^3 or have a history of acquired immune deficiency syndrome (AIDS) indicator conditions"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 34,
                    "description": "Intrinsic lung disease resulting in dyspnea"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 35,
                    "description": "History of hospitalization in past 12 months for diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic nonketotic syndrome (HHNS)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 36,
                    "description": "Active infection or chronic infection requiring chronic suppressive antibiotics"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 37,
                    "description": "Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 38,
                    "description": "Conditions that would prohibit administration of corticosteroids"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 39,
                    "description": "Chronic daily treatment with corticosteroids with a dose of >= 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 40,
                    "description": "Known hypersensitivity to any of the study drugs or excipients, e.g., polysorbate 80 and Cremophor EL"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 41,
                    "description": "Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 42,
                    "description": "Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 43,
                    "description": "Pregnancy or lactation at the time of study entry; (note: pregnancy testing according to institutional standards for women of childbearing potential must be performed within 2 weeks prior to randomization)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 44,
                    "description": "Use of any investigational product within 4 weeks prior to randomization"
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": "PRIMARY OBJECTIVES:\r\nI. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin (doxorubicin hydrochloride)/cyclophosphamide followed by paclitaxel will improve the invasive disease-free survival (IDFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer.\r\n\r\nSECONDARY OBJECTIVES:\r\nI. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the overall survival (OS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer.\r\nII. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the breast cancer-free survival (BCFS) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. \r\nIII. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the recurrence-free interval (RFI) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. \r\nIV. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel will improve the distant recurrence-free interval (DRFI) compared to doxorubicin/cyclophosphamide followed by paclitaxel when administered to patients with operable node-positive or high-risk node-negative triple-negative breast cancer. \r\nV. To determine the toxicity of doxorubicin/cyclophosphamide followed by paclitaxel administered concurrently with carboplatin compared to the toxicity of doxorubicin/cyclophosphamide followed by paclitaxel alone.\r\nVI. To determine if germline BRCA status is associated with benefit in IDFS or OS from the addition of carboplatin to an adjuvant chemotherapy regimen of doxorubicin/cyclophosphamide followed by paclitaxel in patients with operable node-positive or high-risk node-negative triple-negative breast cancer.\r\nVII. To determine if the addition of carboplatin will improve the RFI among the homologous recombination (HR) deficient patients as determined by the homologous recombination deficiency (HRD) score.\r\nVIII. To determine whether the efficacy of carboplatin on RFI in HR-deficient patients differs from that in patients who are not HR-deficient.\r\nIX. To collect tissue and blood samples at several occasions for future biomarkers development in predicting risk of breast cancer recurrence in patients with operable node-positive or high-risk node-negative triple-negative breast cancer treated with doxorubicin/cyclophosphamide followed by paclitaxel with or without carboplatin and predicting benefit from the addition of carboplatin among these patients.\r\n\r\nOUTLINE: Patients are randomized to 1 of 2 treatment arms. \r\n\r\nARM I (DOXORUBICIN HYDROCHLORIDE [A] CYCLOPHOSPHAMIDE [C]-->WEEKLY PACLITAXEL [WP]): Patients receive doxorubicin hydrochloride intravenously (IV) over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive paclitaxel IV over 60 minutes on day 1. Treatment repeats weekly for 12 cycles in the absence of disease progression or unacceptable toxicity. \r\n\r\nARM II (AC-->WP + CARBOPLATIN): Patients receive doxorubicin hydrochloride and cyclophosphamide as in Arm I. Patients then receive paclitaxel IV over 60 minutes on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.\r\n\r\nAfter completion of study treatment, patients are followed up every 6 months for 5 years and then every 12 months for 5 years.",
        "official_title": "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer",
        "_phase_sort_order": 0,
        "collaborators": [
            {
                "name": "National Cancer Institute",
                "functional_role": "FUNDING_SOURCE"
            }
        ],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "From randomization until local recurrence (invasive or ductal carcinoma in situ [DCIS]), regional recurrence, or distant recurrence, contralateral breast cancer (invasive or DCIS), or death from any causes, assessed up to 10 years",
                "name": "Breast cancer-free survival (BCFS)",
                "description": "The stratified log-rank tests will be 2-sided with significance level 0.05. Treatment efficacy in these secondary endpoints will be assessed by Cox models adjusting for clinical factors such as age, number of positive nodes, BRCA mutation status, tumor size, and tumor grade.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From randomization until distant metastasis or death from breast cancer, regardless of occurrence of any intervening local or regional recurrences, contralateral breast cancers, or non-breast second primary cancers, assessed up to 10 years",
                "name": "Distant recurrence-free interval (DRFI)",
                "description": "The stratified log-rank tests will be 2-sided with significance level 0.05. Treatment efficacy in these secondary endpoints will be assessed by Cox models adjusting for clinical factors such as age, number of positive nodes, BRCA mutation status, tumor size, and tumor grade.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 10 years",
                "name": "Frequencies of adverse events",
                "description": "Will be categorized using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Frequencies of all adverse events during the treatment period will be tabulated by treatment, toxicity type, and grade. The Pearson Chi-squared test with continuity adjustment will be used to compare toxicity grades in each type between the two treatment regimens. The test will be 2-sided with significance level 0.05.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 10 years",
                "name": "Invasive disease-free survival (IDFS)",
                "description": "IDFS events are local invasive recurrence after mastectomy, local invasive recurrence in the ipsilateral breast after lumpectomy, regional recurrence, distant recurrence, contralateral invasive breast cancer, second non-breast primary cancer (excluding squamous or basal cell carcinoma of the skin), or death from any cause before recurrence or second primary cancer. IDFS will be compared between the two treatment arms by the stratified log-rank test. The Kaplan-Meier estimates will be calculated separately for patients under the different treatment regimens. An exploratory analysis will be performed to determine whether the treatment efficacy differs between patients with < 1% estrogen receptor (ER) and progesterone receptor (PgR) and patients with 1-9% ER and PgR staining by immunohistochemistry",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "From randomization until death from any cause, assessed up to 10 years",
                "name": "Overall survival (OS)",
                "description": "The stratified log-rank tests will be 2-sided with significance level 0.05. Treatment efficacy in these secondary endpoints will be assessed by Cox models adjusting for clinical factors such as age, number of positive nodes, BRCA mutation status, tumor size, and tumor grade.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From randomization until invasive local, regional, or distant recurrence, or death from breast cancer (censored for death from other causes), assessed up to 10 years",
                "name": "Recurrence-free interval (RFI)",
                "description": "The stratified log-rank tests will be 2-sided with significance level 0.05. Treatment efficacy in these secondary endpoints will be assessed by Cox models adjusting for clinical factors such as age, number of positive nodes, BRCA mutation status, tumor size, and tumor grade.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 10 years",
                "name": "Treatment efficacy",
                "description": "An exploratory analysis will be performed to determine whether the treatment efficacy differs between patients with < 1% estrogen receptor (ER) and progesterone receptor (PgR) and patients with 1-9% ER and PgR staining by immunohistochemistry.",
                "type_code": "OTHER_PRE_SPECIFIED"
            }
        ],
        "phase": "III",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 2,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT02488967",
        "biomarkers": [
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "ER",
                    "ESR1",
                    "Estrogen Receptor 1 Gene"
                ],
                "nci_thesaurus_concept_id": "C38349",
                "name": "ESR1 Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "reference_gene"
                ],
                "ancestors": [
                    "C16612",
                    "C54362",
                    "C20709",
                    "C20103",
                    "C20420",
                    "C21295"
                ],
                "parents": [
                    "C20709"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "ER Alpha Positive",
                    "ER Positive",
                    "ER+",
                    "ER-Alpha Positive",
                    "ERA Positive",
                    "ESR Positive",
                    "ESR1 Positive",
                    "ESRA Positive",
                    "ESTRR Positive",
                    "Estrogen Receptor 1 Positive",
                    "Estrogen Receptor Alpha Positive",
                    "NR3A1 Positive",
                    "Nuclear Receptor Subfamily 3 Group A Member 1 Positive",
                    "Positive",
                    "Positive Estrogen Receptor"
                ],
                "nci_thesaurus_concept_id": "C15492",
                "name": "Estrogen Receptor Positive",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C35682",
                    "C20709",
                    "C16150",
                    "C38349",
                    "C177692",
                    "C3367",
                    "C36292",
                    "C21295",
                    "C54362",
                    "C28656",
                    "C101267",
                    "C188928",
                    "C16612",
                    "C20103",
                    "C94299",
                    "C77140",
                    "C20420"
                ],
                "parents": [
                    "C101267",
                    "C16150",
                    "C38349"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Genes"
                ],
                "nci_thesaurus_concept_id": "C16612",
                "name": "Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "branch"
                ],
                "ancestors": [],
                "parents": [],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "ER Alpha Status",
                    "ER Status",
                    "ER-Alpha Status",
                    "ERA Status",
                    "ESR Status",
                    "ESR1 Status",
                    "ESRA Status",
                    "ESTRR Status",
                    "Estrogen Receptor",
                    "Estrogen Receptor 1 Status",
                    "Estrogen Receptor Alpha Status",
                    "NR3A1 Status",
                    "Nuclear Receptor Subfamily 3 Group A Member 1 Status"
                ],
                "nci_thesaurus_concept_id": "C16150",
                "name": "Estrogen Receptor Status",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C36292",
                    "C16612",
                    "C188928",
                    "C54362",
                    "C77140",
                    "C3367",
                    "C94299",
                    "C20420",
                    "C21295",
                    "C20103",
                    "C20709",
                    "C38349"
                ],
                "parents": [
                    "C188928",
                    "C38349"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Observable Entity"
                ],
                "nci_thesaurus_concept_id": "C3367",
                "name": "Finding",
                "semantic_types": [
                    "Finding"
                ],
                "type": [
                    "branch"
                ],
                "ancestors": [],
                "parents": [],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "PgR Status",
                    "Progesterone Receptor"
                ],
                "nci_thesaurus_concept_id": "C16149",
                "name": "Progesterone Receptor Status",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C36292",
                    "C16612",
                    "C188928",
                    "C28656",
                    "C54362",
                    "C77140",
                    "C3367",
                    "C94299",
                    "C20420",
                    "C21295",
                    "C20103",
                    "C20709"
                ],
                "parents": [
                    "C188928",
                    "C28656"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "HR Status"
                ],
                "nci_thesaurus_concept_id": "C188928",
                "name": "Hormone Receptor Status",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C94299",
                    "C36292",
                    "C3367",
                    "C77140"
                ],
                "parents": [
                    "C94299"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C165744",
                "name": "Hormone Receptor Negative",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C36292",
                    "C188928",
                    "C77140",
                    "C35681",
                    "C3367",
                    "C94299",
                    "C165233"
                ],
                "parents": [
                    "C165233",
                    "C188928"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "ERBB2 Status",
                    "Her2/Neu Value"
                ],
                "nci_thesaurus_concept_id": "C16152",
                "name": "HER2/Neu Status",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C36292",
                    "C16612",
                    "C77140",
                    "C3367",
                    "C94299",
                    "C20719",
                    "C21295",
                    "C20103",
                    "C25870",
                    "C17756",
                    "C25872",
                    "C25871",
                    "C21281"
                ],
                "parents": [
                    "C17756",
                    "C94299"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Absent",
                    "LOST",
                    "Loss of Expression",
                    "Negative",
                    "Not Expressed"
                ],
                "nci_thesaurus_concept_id": "C165233",
                "name": "Expression Negative",
                "semantic_types": [
                    "Cell or Molecular Dysfunction"
                ],
                "type": [],
                "ancestors": [
                    "C77140",
                    "C3367",
                    "C35681"
                ],
                "parents": [
                    "C35681"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C54362",
                "name": "Transcription Regulation Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C16612"
                ],
                "parents": [
                    "C16612"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "ER Alpha Negative",
                    "ER Negative",
                    "ER-",
                    "ER-Alpha Negative",
                    "ERA Negative",
                    "ESR Negative",
                    "ESR1 Negative",
                    "ESRA Negative",
                    "ESTRR Negative",
                    "Estrogen Receptor 1 Negative",
                    "Estrogen Receptor Alpha Negative",
                    "NR3A1 Negative",
                    "Negative",
                    "Negative Estrogen Receptor",
                    "Nuclear Receptor Subfamily 3 Group A Member 1 Negative"
                ],
                "nci_thesaurus_concept_id": "C15493",
                "name": "Estrogen Receptor Negative",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C36292",
                    "C16612",
                    "C16150",
                    "C188928",
                    "C54362",
                    "C35681",
                    "C77140",
                    "C3367",
                    "C94299",
                    "C20420",
                    "C21295",
                    "C20103",
                    "C165233",
                    "C165744",
                    "C20709",
                    "C38349"
                ],
                "parents": [
                    "C16150",
                    "C165744",
                    "C38349"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C101267",
                "name": "Hormone Receptor Positive",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C35682",
                    "C20709",
                    "C38349",
                    "C177692",
                    "C3367",
                    "C36292",
                    "C21295",
                    "C54362",
                    "C28656",
                    "C16612",
                    "C188928",
                    "C20103",
                    "C94299",
                    "C77140",
                    "C20420"
                ],
                "parents": [
                    "C177692",
                    "C188928",
                    "C28656",
                    "C38349"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C20103",
                "name": "Receptor Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C21295",
                    "C16612"
                ],
                "parents": [
                    "C21295"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C21281",
                "name": "Enzyme Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C16612"
                ],
                "parents": [
                    "C16612"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C25872",
                "name": "Kinase Family Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C25870",
                    "C16612",
                    "C25871",
                    "C21281"
                ],
                "parents": [
                    "C25871"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "ERBB2",
                    "Erb-b2 Receptor Tyrosine Kinase 2 Gene",
                    "HER2",
                    "HER2/Neu",
                    "NEU"
                ],
                "nci_thesaurus_concept_id": "C17756",
                "name": "ERBB2 Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "reference_gene"
                ],
                "ancestors": [
                    "C16612",
                    "C20719",
                    "C21295",
                    "C25871",
                    "C25872",
                    "C25870",
                    "C20103",
                    "C21281"
                ],
                "parents": [
                    "C20719"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C21295",
                "name": "Ligand Binding Protein Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C16612"
                ],
                "parents": [
                    "C16612"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "PGR Positive",
                    "PR Positive",
                    "PR+",
                    "Positive"
                ],
                "nci_thesaurus_concept_id": "C15496",
                "name": "Progesterone Receptor Positive",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C16612",
                    "C36292",
                    "C54362",
                    "C188928",
                    "C77140",
                    "C101267",
                    "C177692",
                    "C20709",
                    "C94299",
                    "C20103",
                    "C28656",
                    "C3367",
                    "C20420",
                    "C38349",
                    "C21295",
                    "C35682",
                    "C16149"
                ],
                "parents": [
                    "C101267",
                    "C16149",
                    "C28656"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "ERBB2 Negative",
                    "HER-2 Negative",
                    "HER2 Negative"
                ],
                "nci_thesaurus_concept_id": "C68749",
                "name": "HER2/Neu Negative",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C36292",
                    "C17756",
                    "C16612",
                    "C77140",
                    "C35681",
                    "C3367",
                    "C94299",
                    "C20719",
                    "C21295",
                    "C20103",
                    "C25870",
                    "C165233",
                    "C16152",
                    "C25872",
                    "C25871",
                    "C21281"
                ],
                "parents": [
                    "C16152",
                    "C165233",
                    "C17756"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Diagnostic Test Result",
                    "Test Result"
                ],
                "nci_thesaurus_concept_id": "C77140",
                "name": "Clinical Test Result",
                "semantic_types": [
                    "Finding"
                ],
                "type": [],
                "ancestors": [
                    "C3367"
                ],
                "parents": [
                    "C3367"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "ER-Negative PR-Negative ERBB2-Negative",
                    "ER-PR-HER2/neu-",
                    "ER-negative PR-negative HER2/neu-negative",
                    "ER/PR/HER2 Negative",
                    "ESR1/PGR/ERBB2 Negative Finding",
                    "Triple Negative Breast Cancer Finding",
                    "Triple Negative Breast Cancer Result",
                    "Triple-Negative Breast Cancer Result",
                    "triple-negative breast cancer"
                ],
                "nci_thesaurus_concept_id": "C71428",
                "name": "Triple-Negative Breast Cancer Finding",
                "semantic_types": [
                    "Finding"
                ],
                "type": [],
                "ancestors": [
                    "C165233",
                    "C38349",
                    "C77140",
                    "C20709",
                    "C25870",
                    "C28656",
                    "C21281",
                    "C21295",
                    "C20719",
                    "C3367",
                    "C25872",
                    "C17756",
                    "C25871",
                    "C35681",
                    "C20103",
                    "C20420",
                    "C16612",
                    "C94299",
                    "C36292",
                    "C54362"
                ],
                "parents": [
                    "C165233",
                    "C17756",
                    "C28656",
                    "C38349",
                    "C94299"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TRIAL",
                "synonyms": [
                    "Negative",
                    "PGR Negative",
                    "PR Negative",
                    "PR-"
                ],
                "nci_thesaurus_concept_id": "C15497",
                "name": "Progesterone Receptor Negative",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C36292",
                    "C16612",
                    "C188928",
                    "C28656",
                    "C35681",
                    "C54362",
                    "C77140",
                    "C3367",
                    "C94299",
                    "C20420",
                    "C21295",
                    "C20103",
                    "C16149",
                    "C165744",
                    "C20709",
                    "C165233"
                ],
                "parents": [
                    "C16149",
                    "C165744",
                    "C28656"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Negative"
                ],
                "nci_thesaurus_concept_id": "C35681",
                "name": "Negative Test Result",
                "semantic_types": [
                    "Finding"
                ],
                "type": [],
                "ancestors": [
                    "C77140",
                    "C3367"
                ],
                "parents": [
                    "C77140"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Positive",
                    "positive test result"
                ],
                "nci_thesaurus_concept_id": "C35682",
                "name": "Positive Laboratory Test Result",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C3367",
                    "C36292",
                    "C77140"
                ],
                "parents": [
                    "C36292"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C25870",
                "name": "Transferase Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C16612",
                    "C21281"
                ],
                "parents": [
                    "C21281"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C20719",
                "name": "Receptor Tyrosine Kinase Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C25870",
                    "C16612",
                    "C20103",
                    "C21295",
                    "C21281",
                    "C25872",
                    "C25871"
                ],
                "parents": [
                    "C20103",
                    "C25872"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "PGR",
                    "PR",
                    "Progesterone Receptor Gene"
                ],
                "nci_thesaurus_concept_id": "C28656",
                "name": "PGR Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [
                    "reference_gene"
                ],
                "ancestors": [
                    "C16612",
                    "C54362",
                    "C20709",
                    "C20103",
                    "C20420",
                    "C21295"
                ],
                "parents": [
                    "C20709"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C94299",
                "name": "Receptor Status",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C36292",
                    "C77140",
                    "C3367"
                ],
                "parents": [
                    "C36292"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "LAB_RESULT",
                    "Lab Findings",
                    "Lab Value",
                    "Laboratory Finding",
                    "Laboratory Report",
                    "Labs",
                    "Test Result",
                    "test_result"
                ],
                "nci_thesaurus_concept_id": "C36292",
                "name": "Laboratory Test Result",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C77140",
                    "C3367"
                ],
                "parents": [
                    "C77140"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C20709",
                "name": "Nuclear Receptor Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C16612",
                    "C54362",
                    "C20103",
                    "C20420",
                    "C21295"
                ],
                "parents": [
                    "C20103",
                    "C20420"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [],
                "nci_thesaurus_concept_id": "C25871",
                "name": "Phosphotransferase Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C25870",
                    "C16612",
                    "C21281"
                ],
                "parents": [
                    "C25870"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Expressed",
                    "Expression Detected"
                ],
                "nci_thesaurus_concept_id": "C177692",
                "name": "Expression Positive",
                "semantic_types": [
                    "Laboratory or Test Result"
                ],
                "type": [],
                "ancestors": [
                    "C35682",
                    "C36292",
                    "C77140",
                    "C3367"
                ],
                "parents": [
                    "C35682"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            },
            {
                "eligibility_criterion": "inclusion",
                "inclusion_indicator": "TREE",
                "synonyms": [
                    "Proto-Oncogene, Transcription Factor"
                ],
                "nci_thesaurus_concept_id": "C20420",
                "name": "Transcription Factor Gene",
                "semantic_types": [
                    "Gene or Genome"
                ],
                "type": [],
                "ancestors": [
                    "C16612",
                    "C54362"
                ],
                "parents": [
                    "C54362"
                ],
                "assay_purpose": "Eligibility Criterion - Inclusion"
            }
        ],
        "classification_code": "Efficacy",
        "current_trial_status_date": "2022-04-22",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Unilateral Breast Carcinoma"
                ],
                "nci_thesaurus_concept_id": "C46073",
                "name": "Unilateral Breast Cancer",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4872"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Adenocarcinoma of Breast",
                    "Mammary adenocarcinoma",
                    "Adenocarcinoma of the Breast"
                ],
                "nci_thesaurus_concept_id": "C5214",
                "name": "Breast Adenocarcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4872",
                    "C2852"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Breast Cancer Stage IIA",
                    "Stage IIA Breast Cancer AJCC v7",
                    "Breast Carcinoma Stage IIA",
                    "Stage IIA Breast Carcinoma",
                    "Stage IIA Breast Cancer AJCC v6",
                    "Stage IIA Breast Cancer AJCC v6 and v7"
                ],
                "nci_thesaurus_concept_id": "C5454",
                "name": "Stage IIA Breast Cancer",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C7768"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Breast Cancer Stage IIB",
                    "Stage IIB Breast Carcinoma",
                    "Stage IIB Breast Cancer AJCC v6",
                    "Breast Carcinoma Stage IIB",
                    "Stage IIB Breast Cancer AJCC v6 and v7",
                    "Stage IIB Breast Cancer AJCC v7"
                ],
                "nci_thesaurus_concept_id": "C5455",
                "name": "Stage IIB Breast Cancer",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C7768"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Triple Negative Breast Carcinoma",
                    "Triple-Negative Breast Carcinoma"
                ],
                "nci_thesaurus_concept_id": "C71732",
                "name": "Triple-Negative Breast Cancer",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C53553",
                    "C165743"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Stage II Breast Cancer AJCC v6",
                    "Stage II Breast Cancer AJCC v6 and v7",
                    "Stage II Breast Carcinoma",
                    "Carcinoma of the Breast Stage II",
                    "Carcinoma of Breast Stage II",
                    "Breast Cancer Stage II",
                    "Stage II Breast Cancer AJCC v7"
                ],
                "nci_thesaurus_concept_id": "C7768",
                "name": "Stage II Breast Cancer",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C91230",
                    "C90513"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Stage IIIA Breast Carcinoma",
                    "Breast Cancer Stage IIIA",
                    "Stage IIIA Breast Cancer AJCC v7",
                    "Breast Carcinoma Stage IIIA"
                ],
                "nci_thesaurus_concept_id": "C7770",
                "name": "Stage IIIA Breast Cancer",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C88376"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Stage IA Breast Cancer AJCC v7"
                ],
                "nci_thesaurus_concept_id": "C85835",
                "name": "Stage IA Breast Cancer",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C88375"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Stage IB Breast Cancer AJCC v7"
                ],
                "nci_thesaurus_concept_id": "C85836",
                "name": "Stage IB Breast Cancer",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C88375"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Stage I Breast Cancer AJCC v7"
                ],
                "nci_thesaurus_concept_id": "C88375",
                "name": "Stage I Breast Cancer",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C91230"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Stage IIIC Breast Cancer AJCC v7"
                ],
                "nci_thesaurus_concept_id": "C88377",
                "name": "Stage IIIC Breast Cancer",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C88376"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "infiltrating breast cancer",
                    "Invasive Carcinoma of the Breast",
                    "Infiltrating Carcinoma of the Breast",
                    "Invasive Breast Carcinoma",
                    "Invasive Mammary Carcinoma",
                    "Invasive Carcinoma of Breast",
                    "Infiltrating Breast Carcinoma",
                    "Infiltrating Carcinoma of Breast"
                ],
                "nci_thesaurus_concept_id": "C9245",
                "name": "Invasive Breast Cancer",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4872",
                    "C9480"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Cancer of the Breast",
                    "Breast cancer, NOS",
                    "Cancer of Breast",
                    "Carcinoma of the Breast",
                    "Mammary Carcinoma",
                    "Carcinoma of Breast",
                    "Breast Carcinoma"
                ],
                "nci_thesaurus_concept_id": "C4872",
                "name": "Breast Cancer",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C9335",
                    "C2916"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Breast Diseases",
                    "Breast Disease"
                ],
                "nci_thesaurus_concept_id": "C26709",
                "name": "Breast Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C27551"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Tumor_Morphology",
                    "Tumor Morphology"
                ],
                "nci_thesaurus_concept_id": "C4741",
                "name": "Neoplasm by Morphology",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm of Breast",
                    "Tumor of the Breast",
                    "Breast Tumor",
                    "Tumor of Breast",
                    "Neoplasm of the Breast"
                ],
                "nci_thesaurus_concept_id": "C2910",
                "name": "Breast Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C26709",
                    "C3263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "ER and PR Negative Breast Carcinoma",
                    "Hormone Receptor Negative Breast Adenocarcinoma",
                    "Estrogen Receptor and Progesterone Receptor Negative Breast Carcinoma",
                    "Hormone Receptor-Negative Breast Carcinoma"
                ],
                "nci_thesaurus_concept_id": "C165743",
                "name": "Hormone Receptor Negative Breast Carcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C5214"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C3263",
                "name": "Neoplasm by Site",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Epithelioma, malignant",
                    "Epithelioma",
                    "Epithelial Neoplasms, NOS"
                ],
                "nci_thesaurus_concept_id": "C3709",
                "name": "Epithelial Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4741"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Disease by Site"
                ],
                "nci_thesaurus_concept_id": "C27551",
                "name": "Disorder by Site",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplastic Disease",
                    "Neoplastic Growth",
                    "Neoplasm",
                    "Neoplasm, NOS",
                    "tumor",
                    "Neoplasia",
                    "Neoplasms, NOS",
                    "Tumor, NOS"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Malignancy",
                    "Malignant Growth",
                    "Cancer",
                    "CA",
                    "Malignant Tumor",
                    "Unclassified tumor, malignant",
                    "Tumor, malignant, NOS",
                    "Malignant Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Tumor of Breast",
                    "Malignant Neoplasm of Breast",
                    "Malignant Tumor of the Breast",
                    "Malignant Breast Tumor",
                    "Malignant Neoplasm of the Breast"
                ],
                "nci_thesaurus_concept_id": "C9335",
                "name": "Malignant Breast Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C2910"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Adenocarcinoma, NOS",
                    "ADENOCARCINOMA, MALIGNANT"
                ],
                "nci_thesaurus_concept_id": "C2852",
                "name": "Adenocarcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2916",
                    "C7132"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease type",
                    "Diseases",
                    "Disease",
                    "Disease or Disorder",
                    "disease_term",
                    "Disorder",
                    "Diseases and Disorders",
                    "disease term",
                    "condition",
                    "Disorders",
                    "Disease or Disorder, Non-Neoplastic",
                    "Diagnosis",
                    "disease_type"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C53553",
                "name": "Breast Carcinoma by Gene Expression Profile",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C5214"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Glandular Cell Epithelial Neoplasm",
                    "Glandular Cell Epithelium Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C7132",
                "name": "Glandular Cell Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3709"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Carcinoma",
                    "Epithelial Carcinoma",
                    "Malignant Epithelial Neoplasm",
                    "Malignant Epithelioma",
                    "Malignant Epithelial Tumor",
                    "Carcinoma, NOS",
                    "Epithelial tumor, malignant",
                    "CARCINOMA, MALIGNANT",
                    "Epithelioma Malignant"
                ],
                "nci_thesaurus_concept_id": "C2916",
                "name": "Other Carcinoma",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C9305",
                    "C3709"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C9480",
                "name": "Invasive Carcinoma",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C8505",
                    "C2916"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Breast Carcinoma by AJCC v6 Stage"
                ],
                "nci_thesaurus_concept_id": "C90513",
                "name": "Breast Cancer by AJCC v6 Stage",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C4872"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Breast Carcinoma by AJCC v7 Stage"
                ],
                "nci_thesaurus_concept_id": "C91230",
                "name": "Breast Cancer by AJCC v7 Stage",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C4872"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "invasive cancer",
                    "infiltrating cancer",
                    "Infiltrating Malignant Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C8505",
                "name": "Invasive Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Stage III Breast Cancer AJCC v7"
                ],
                "nci_thesaurus_concept_id": "C88376",
                "name": "Stage III Breast Cancer",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C91230"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "NRG-BR003",
        "active_sites_count": 12,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Cytotoxic Antineoplastic Agent",
                            "Antineoplastic Cytotoxic Agent",
                            "Cytotoxic Chemotherapy Agent"
                        ],
                        "nci_thesaurus_concept_id": "C186664",
                        "name": "Cytotoxic Chemotherapeutic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C67502",
                        "name": "Doxorubicin Preparation",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1594"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Protein Inhibitor",
                            "Antineoplastic Protein Antagonist"
                        ],
                        "nci_thesaurus_concept_id": "C129824",
                        "name": "Antineoplastic Protein Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2189"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Taxanes"
                        ],
                        "nci_thesaurus_concept_id": "C1490",
                        "name": "Taxane Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C860"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Antibiotics",
                            "Anticancer Antibiotic",
                            "Anticancer Antibiotics",
                            "Antitumor Antibiotics",
                            "Antitumor Antibiotic"
                        ],
                        "nci_thesaurus_concept_id": "C259",
                        "name": "Antineoplastic Antibiotic",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C186664"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunomodulators",
                            "Biological Response Modifier",
                            "Immune Mediators",
                            "Immune Regulators",
                            "Immunotherapeutic Agent",
                            "Biomodulators",
                            "Immunomodulating Agent",
                            "Immunomodulatory Agent",
                            "Immunotherapy Agent",
                            "BRM",
                            "Immunopotentiators",
                            "Immune Modulators"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anthracyclines",
                            "Chemotherapy, Cancer, Anthracyclines"
                        ],
                        "nci_thesaurus_concept_id": "C1594",
                        "name": "Anthracycline Antineoplastic Antibiotic",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1968",
                            "C259",
                            "C2115"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Topoisomerase-II Inhibitors"
                        ],
                        "nci_thesaurus_concept_id": "C1968",
                        "name": "Topoisomerase-II Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1748"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2189",
                        "name": "Signal Transduction Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-Tumor Agents",
                            "Antineoplastics",
                            "Tumor-Specific Treatment Agents",
                            "Anti-Tumor Drugs",
                            "Antineoplastic Drugs",
                            "Antiproliferative Drugs",
                            "Anti-Cancer Agents",
                            "Antiproliferative Agents",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Cancer Drug"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Fosfaseron",
                            "Cytophosphan",
                            "CYCLO-cell",
                            "Genuxal",
                            "Cycloblastine",
                            "Cicloxal",
                            "Carloxan",
                            "Cyclostin",
                            "Ledoxina",
                            "Cyclostine",
                            "Cycloblastin",
                            "Genoxal"
                        ],
                        "nci_thesaurus_concept_id": "C405",
                        "name": "Cyclophosphamide",
                        "description": "A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C574",
                            "C697"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1913",
                        "name": "Drug or Chemical by Structure",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C718",
                        "name": "Organic Chemical",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1913"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Enzyme Antagonist",
                            "Enzyme Inhibitor Agent",
                            "Enzyme Inhibitor Drug"
                        ],
                        "nci_thesaurus_concept_id": "C471",
                        "name": "Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Chemotherapy Alkylators",
                            "Chemotherapy Alkylating Agents"
                        ],
                        "nci_thesaurus_concept_id": "C1590",
                        "name": "Antineoplastic Alkylating Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2842"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Terpenes"
                        ],
                        "nci_thesaurus_concept_id": "C860",
                        "name": "Terpene Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C552",
                            "C616"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2161",
                        "name": "DNA Groove Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2842"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Hydrocarbons"
                        ],
                        "nci_thesaurus_concept_id": "C552",
                        "name": "Hydrocarbon",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C718"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Bristaxol",
                            "Taxol Konzentrat",
                            "Asotax",
                            "Praxel",
                            "Anzatax"
                        ],
                        "nci_thesaurus_concept_id": "C1411",
                        "name": "Paclitaxel",
                        "description": "A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C1490",
                            "C67437"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Enzyme Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C129825",
                        "name": "Antineoplastic Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C471",
                            "C129824"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C697",
                        "name": "Nitrogen Mustard Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2114"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Lipids"
                        ],
                        "nci_thesaurus_concept_id": "C616",
                        "name": "Lipid",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C718"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Pharmacologic Agent",
                            "Pharmaceuticals",
                            "Pharmaceutical Agent",
                            "Drug Substance",
                            "Drug",
                            "Agent",
                            "Pharmacological Substance"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Topoisomerase Inhibitors",
                            "DNA Topoisomerase Inhibitors"
                        ],
                        "nci_thesaurus_concept_id": "C1748",
                        "name": "Topoisomerase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C129825"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2114",
                        "name": "Mustard Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1590"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunosuppressive Agents"
                        ],
                        "nci_thesaurus_concept_id": "C574",
                        "name": "Immunosuppressant",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Doxolem",
                            "Adriacin",
                            "Adriblastine",
                            "Farmiblastina",
                            "Rubex",
                            "Adriamycin",
                            "DOXO-CELL",
                            "Doxorubin",
                            "Adrimedac",
                            "Adriblastina"
                        ],
                        "nci_thesaurus_concept_id": "C1326",
                        "name": "Doxorubicin Hydrochloride",
                        "description": "The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.  Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health prof",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C67502"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Tubulin Binding Agents"
                        ],
                        "nci_thesaurus_concept_id": "C25974",
                        "name": "Tubulin Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C273"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C456",
                        "name": "Doxorubicin",
                        "description": null,
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C67502"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2115",
                        "name": "DNA Minor Groove Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2161"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2842",
                        "name": "DNA Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C186664"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Taxane-Site Binding Agent"
                        ],
                        "nci_thesaurus_concept_id": "C67437",
                        "name": "Taxane-Pocket Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C25974"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Mitosis Inhibitor Drugs",
                            "Mitosis Inhibitors",
                            "Mitotic Inhibitor Drugs",
                            "Antimitotics",
                            "Mitosis Inhibitor Agents",
                            "Mitotic Inhibitors",
                            "Antimitotic Drugs",
                            "Mitotic Inhibitor Agents",
                            "Microtubular Function Inhibitors"
                        ],
                        "nci_thesaurus_concept_id": "C273",
                        "name": "Antimitotic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C186664"
                        ]
                    }
                ],
                "name": "Arm I (AC-->WP)",
                "description": "Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive paclitaxel IV over 60 minutes on day 1. Treatment repeats weekly for 12 cycles in the absence of disease progression or unacceptable toxicity.",
                "type": "ACTIVE_COMPARATOR"
            },
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Cytotoxic Antineoplastic Agent",
                            "Antineoplastic Cytotoxic Agent",
                            "Cytotoxic Chemotherapy Agent"
                        ],
                        "nci_thesaurus_concept_id": "C186664",
                        "name": "Cytotoxic Chemotherapeutic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C67502",
                        "name": "Doxorubicin Preparation",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1594"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Protein Inhibitor",
                            "Antineoplastic Protein Antagonist"
                        ],
                        "nci_thesaurus_concept_id": "C129824",
                        "name": "Antineoplastic Protein Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2189"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Taxanes"
                        ],
                        "nci_thesaurus_concept_id": "C1490",
                        "name": "Taxane Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C860"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Platinum Agents",
                            "Platinum-Based Chemotherapy"
                        ],
                        "nci_thesaurus_concept_id": "C1450",
                        "name": "Platinum Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C798",
                            "C2163",
                            "C1590"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Antibiotics",
                            "Anticancer Antibiotic",
                            "Anticancer Antibiotics",
                            "Antitumor Antibiotics",
                            "Antitumor Antibiotic"
                        ],
                        "nci_thesaurus_concept_id": "C259",
                        "name": "Antineoplastic Antibiotic",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C186664"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunomodulators",
                            "Biological Response Modifier",
                            "Immune Mediators",
                            "Immune Regulators",
                            "Immunotherapeutic Agent",
                            "Biomodulators",
                            "Immunomodulating Agent",
                            "Immunomodulatory Agent",
                            "Immunotherapy Agent",
                            "BRM",
                            "Immunopotentiators",
                            "Immune Modulators"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Paraplatin AQ",
                            "Carbotec",
                            "Displata",
                            "Paraplatine",
                            "Blastocarb",
                            "Ercar",
                            "Novoplatinum",
                            "Ribocarbo",
                            "Carbosin",
                            "Carbosol",
                            "Platinwas",
                            "Nealorin",
                            "Carboplat"
                        ],
                        "nci_thesaurus_concept_id": "C1282",
                        "name": "Carboplatin",
                        "description": "A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C1450"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anthracyclines",
                            "Chemotherapy, Cancer, Anthracyclines"
                        ],
                        "nci_thesaurus_concept_id": "C1594",
                        "name": "Anthracycline Antineoplastic Antibiotic",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1968",
                            "C259",
                            "C2115"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Topoisomerase-II Inhibitors"
                        ],
                        "nci_thesaurus_concept_id": "C1968",
                        "name": "Topoisomerase-II Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1748"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-Tumor Agents",
                            "Antineoplastics",
                            "Tumor-Specific Treatment Agents",
                            "Anti-Tumor Drugs",
                            "Antineoplastic Drugs",
                            "Antiproliferative Drugs",
                            "Anti-Cancer Agents",
                            "Antiproliferative Agents",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Cancer Drug"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2189",
                        "name": "Signal Transduction Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Fosfaseron",
                            "Cytophosphan",
                            "CYCLO-cell",
                            "Genuxal",
                            "Cycloblastine",
                            "Cicloxal",
                            "Carloxan",
                            "Cyclostin",
                            "Ledoxina",
                            "Cyclostine",
                            "Cycloblastin",
                            "Genoxal"
                        ],
                        "nci_thesaurus_concept_id": "C405",
                        "name": "Cyclophosphamide",
                        "description": "A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.  In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C574",
                            "C697"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1913",
                        "name": "Drug or Chemical by Structure",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C718",
                        "name": "Organic Chemical",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1913"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Enzyme Antagonist",
                            "Enzyme Inhibitor Agent",
                            "Enzyme Inhibitor Drug"
                        ],
                        "nci_thesaurus_concept_id": "C471",
                        "name": "Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Chemotherapy Alkylators",
                            "Chemotherapy Alkylating Agents"
                        ],
                        "nci_thesaurus_concept_id": "C1590",
                        "name": "Antineoplastic Alkylating Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2842"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Terpenes"
                        ],
                        "nci_thesaurus_concept_id": "C860",
                        "name": "Terpene Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C552",
                            "C616"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2161",
                        "name": "DNA Groove Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2842"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Hydrocarbons"
                        ],
                        "nci_thesaurus_concept_id": "C552",
                        "name": "Hydrocarbon",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C718"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Bristaxol",
                            "Taxol Konzentrat",
                            "Asotax",
                            "Praxel",
                            "Anzatax"
                        ],
                        "nci_thesaurus_concept_id": "C1411",
                        "name": "Paclitaxel",
                        "description": "A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C1490",
                            "C67437"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Enzyme Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C129825",
                        "name": "Antineoplastic Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C471",
                            "C129824"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C697",
                        "name": "Nitrogen Mustard Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2114"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Lipids"
                        ],
                        "nci_thesaurus_concept_id": "C616",
                        "name": "Lipid",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C718"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Pharmacologic Agent",
                            "Pharmaceuticals",
                            "Pharmaceutical Agent",
                            "Drug Substance",
                            "Drug",
                            "Agent",
                            "Pharmacological Substance"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Topoisomerase Inhibitors",
                            "DNA Topoisomerase Inhibitors"
                        ],
                        "nci_thesaurus_concept_id": "C1748",
                        "name": "Topoisomerase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C129825"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2114",
                        "name": "Mustard Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1590"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Radiosensitizers",
                            "Radiosensitizing Drugs",
                            "Radiation-Sensitizing Agents",
                            "Radiation Sensitizers",
                            "Radiation-Sensitizing Drugs"
                        ],
                        "nci_thesaurus_concept_id": "C798",
                        "name": "Radiosensitizing Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunosuppressive Agents"
                        ],
                        "nci_thesaurus_concept_id": "C574",
                        "name": "Immunosuppressant",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Doxolem",
                            "Adriacin",
                            "Adriblastine",
                            "Farmiblastina",
                            "Rubex",
                            "Adriamycin",
                            "DOXO-CELL",
                            "Doxorubin",
                            "Adrimedac",
                            "Adriblastina"
                        ],
                        "nci_thesaurus_concept_id": "C1326",
                        "name": "Doxorubicin Hydrochloride",
                        "description": "The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.  Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health prof",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C67502"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Tubulin Binding Agents"
                        ],
                        "nci_thesaurus_concept_id": "C25974",
                        "name": "Tubulin Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C273"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C456",
                        "name": "Doxorubicin",
                        "description": null,
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C67502"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2115",
                        "name": "DNA Minor Groove Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2161"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2163",
                        "name": "DNA Adduct Forming Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2842"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2842",
                        "name": "DNA Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C186664"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Taxane-Site Binding Agent"
                        ],
                        "nci_thesaurus_concept_id": "C67437",
                        "name": "Taxane-Pocket Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C25974"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Mitosis Inhibitor Drugs",
                            "Mitosis Inhibitors",
                            "Mitotic Inhibitor Drugs",
                            "Antimitotics",
                            "Mitosis Inhibitor Agents",
                            "Mitotic Inhibitors",
                            "Antimitotic Drugs",
                            "Mitotic Inhibitor Agents",
                            "Microtubular Function Inhibitors"
                        ],
                        "nci_thesaurus_concept_id": "C273",
                        "name": "Antimitotic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C186664"
                        ]
                    }
                ],
                "name": "Arm II (AC-->WP + carboplatin)",
                "description": "Patients receive doxorubicin hydrochloride and cyclophosphamide as in Arm I. Patients then receive paclitaxel IV over 60 minutes on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2015-00128",
        "why_study_stopped": null,
        "brief_summary": "This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.",
        "brief_title": "Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or without Carboplatin in Treating Patients with Triple-Negative Breast Cancer",
        "status_history": [
            {
                "status_date": "2022-04-22T00:00:00.000003",
                "status": "CLOSED_TO_ACCRUAL"
            },
            {
                "status_date": "2015-06-26T00:00:00.000002",
                "status": "ACTIVE"
            },
            {
                "status_date": "2015-05-19T00:00:00.000001",
                "status": "APPROVED"
            },
            {
                "status_date": "2015-01-07T00:00:00",
                "status": "IN_REVIEW"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 990,
        "prior_therapy": [],
        "_current_trial_status_sort_order": 7,
        "start_date": "2015-06-26",
        "record_verification_date": "2022-04-30",
        "ctep_id": "NRG-BR003",
        "current_trial_status": "Closed to Accrual",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": "OPEN",
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Randomized Controlled Trial"
        },
        "acronym": null,
        "nci_programs": [
            "NCTN"
        ],
        "nci_funded": "Direct",
        "anatomic_sites": [
            "Breast"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": "Vicente Valero",
        "study_source": "National",
        "completion_date": "2023-04-30",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]